Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNIFER MCVIGE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1649596495
CMS profile
29232
Location
AMHERST, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$168,186.49

379 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 5 of 8; records 201–250 of 379 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNIFER MCVIGE

NPI 1649596495 · CMS profile ID 29232

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

AMHERST, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 8; records 201–250 of 379 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649596495?year=2021&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNIFER MCVIGE, NPI 1649596495, CMS profile ID 29232. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 8; records 201–250 of 379 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649596495?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JENNIFER MCVIGE, NPI 1649596495, CMS profile ID 29232. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 8; records 201–250 of 379 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649596495?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JENNIFER MCVIGE, NPI 1649596495, CMS profile ID 29232, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 8; records 201–250 of 379 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1649596495?year=2021&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

379 matching records · $168,186.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 379 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 379.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $7.5506/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564553 CMS
Currax Pharmaceuticals LLC $9.3006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792533903 CMS
Lundbeck LLC $111.7306/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845922717 CMS
Neurelis, Inc. $950.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842872937 CMS
Biohaven Pharmaceuticals, Inc. $36.1806/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564537 CMS
Biohaven Pharmaceuticals, Inc. $50.7906/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564539 CMS
Biohaven Pharmaceuticals, Inc. $51.5606/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564541 CMS
Biohaven Pharmaceuticals, Inc. $66.1806/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564543 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0006/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564545 CMS
Biohaven Pharmaceuticals, Inc. $293.4006/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564547 CMS
Biohaven Pharmaceuticals, Inc. $365.0006/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564549 CMS
Biohaven Pharmaceuticals, Inc. $145.1206/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564551 CMS
Biohaven Pharmaceuticals, Inc. $100.6406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564533 CMS
Biohaven Pharmaceuticals, Inc. $39.9406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564535 CMS
Lilly USA, LLC $21.6906/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819170865 CMS
Currax Pharmaceuticals LLC $14.8306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792533901 CMS
Lundbeck LLC $19.7006/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845922715 CMS
Neurelis, Inc. $114.5606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842872931 CMS
Neurelis, Inc. $1,400.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842872935 CMS
Teva Pharmaceuticals USA, Inc. $96.5006/08/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839502199 CMS
Allergan, Inc. $14.4306/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792872209 CMS
AbbVie Inc. $11.2706/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795621483 CMS
Amgen Inc. $21.2106/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825408821 CMS
Neurelis, Inc. $12.7606/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842872927 CMS
UCB, Inc. $24.5206/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807313841 CMS
Biohaven Pharmaceuticals, Inc. $6.8706/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564531 CMS
Avanir Pharmaceuticals, Inc. $11.3505/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801024799 CMS
Novartis Pharmaceuticals Corporation $15.0705/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813072395 CMS
Currax Pharmaceuticals LLC $3.4305/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792533899 CMS
Amgen Inc. $2,375.0005/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825408839 CMS
Amgen Inc. $2,850.0005/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825408875 CMS
Biohaven Pharmaceuticals, Inc. $16.3105/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564529 CMS
Avanir Pharmaceuticals, Inc. $23.7105/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801025173 CMS
Neurelis, Inc. $2,100.0005/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842872923 CMS
Novartis Pharmaceuticals Corporation $6.8905/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813072391 CMS
AbbVie Inc. $500.0005/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795621477 CMS
Avanir Pharmaceuticals, Inc. $17.5605/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801032549 CMS
UCB, Inc. $14.5505/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807362757 CMS
Currax Pharmaceuticals LLC $8.9105/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792533897 CMS
Amgen Inc. $18.8305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825408833 CMS
Amgen Inc. $119.7305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825408887 CMS
Biohaven Pharmaceuticals, Inc. $5.9005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564527 CMS
Novartis Pharmaceuticals Corporation $17.3505/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813072387 CMS
Teva Pharmaceuticals USA, Inc. $19.2105/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839502237 CMS
Currax Pharmaceuticals LLC $17.7205/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792533895 CMS
LivaNova USA, Inc. $10.9305/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844251661 CMS
Biohaven Pharmaceuticals, Inc. $6.2105/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564523 CMS
Biohaven Pharmaceuticals, Inc. $3.2405/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852564525 CMS
Lundbeck LLC $18.6105/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845922713 CMS
Novartis Pharmaceuticals Corporation $17.8305/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813072383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $137,873.99 367
PY2020 $225,720.37 391
PY2021 $168,186.49 379
PY2022 $139,229.64 415
PY2023 $103,749.58 311
PY2024 $88,162.70 296
PY2025 $118,951.22 297

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $225,328.64 62
PY2024 Recipient $6.54 2
PY2024 Principal investigator $322,216.84 74
PY2023 Recipient $17,037.88 10
PY2023 Principal investigator $133,263.56 27
PY2022 Recipient $1,195.37 4
PY2022 Principal investigator $291,698.59 64
PY2021 Recipient $534.76 2
PY2021 Principal investigator $262,972.41 67
PY2020 Recipient $5,239.88 3
PY2020 Principal investigator $279,757.06 29
PY2019 Recipient $1,142.95 1
PY2019 Principal investigator $431,636.45 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
DENT NEUROLOGIC INSTITUTE
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. No dispute reported 06/30/2026 1202532993
Principal investigator 1 ABBVIE INC. $508.76 12/31/2025 Non-covered Recipient Entity
DENT NEUROLOGIC INSTITUTE
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202532995
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
DENT NEUROLOGIC INSTITUTE
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202532997
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
DENT NEUROLOGIC INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202532999
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 12/19/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244048543
Principal investigator 1 ABBVIE INC. $5,480.00 12/11/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202530098
Principal investigator 1 ABBVIE INC. $395.55 12/04/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202527798
Principal investigator 1 ABBVIE INC. $5,600.00 12/04/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202527800
Principal investigator 1 ABBVIE INC. $25.00 12/04/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202528000
Principal investigator 1 Ipsen Innovation $600.00 12/04/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184302717
Principal investigator 1 Ipsen Innovation $800.00 12/04/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184302719
Principal investigator 1 Ipsen Innovation $1,250.00 12/04/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184302721
Principal investigator 1 Ipsen Innovation $500.00 12/04/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184302723
Principal investigator 1 PFIZER INC. $908.10 11/24/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center INC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228817877
Principal investigator 1 ABBVIE INC. $25,200.00 11/05/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202522731
Principal investigator 1 ABBVIE INC. $2,216.70 11/04/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520961
Principal investigator 1 ABBVIE INC. $2,124.00 11/04/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202520963
Principal investigator 1 ABBVIE INC. $4,083.00 10/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202513845
Principal investigator 1 ABBVIE INC. $2,380.00 10/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202513847
Principal investigator 1 ABBVIE INC. $4,607.55 10/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202513849
Principal investigator 1 ABBVIE INC. $2,530.00 09/04/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202509960
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 09/04/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244048545
Principal investigator 1 ABBVIE INC. $1,306.00 09/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202508320
Principal investigator 1 ABBVIE INC. $1,582.20 09/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202508322
Principal investigator 1 PFIZER INC. $1,986.03 08/27/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center INC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228834180
Principal investigator 1 ABBVIE INC. $4,760.00 08/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202503233
Principal investigator 1 ABBVIE INC. $2,895.75 08/05/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501916
Principal investigator 1 PFIZER INC. $1,815.66 07/29/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228840940
Principal investigator 1 ABBVIE INC. $8,960.00 07/08/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202497308
Principal investigator 1 ABBVIE INC. $3,971.70 07/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202495709
Principal investigator 1 ABBVIE INC. $4,233.00 07/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202495711
Principal investigator 1 ABBVIE INC. $249.75 07/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202495713
Principal investigator 1 ABBVIE INC. $1,120.00 07/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202495715
Principal investigator 1 Eli Lilly and Company $56.25 06/24/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES OF TUCSON
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187884424
Principal investigator 1 PFIZER INC. $2,560.68 06/13/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center INC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228844876
Principal investigator 1 ABBVIE INC. $1,811.70 06/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202488011
Principal investigator 1 ABBVIE INC. $4,037.85 06/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202488013
Principal investigator 1 ABBVIE INC. $653.00 06/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202488015
Principal investigator 1 ABBVIE INC. $2,039.00 06/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202488017
Principal investigator 1 ABBVIE INC. $10,052.00 06/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202488099
Principal investigator 1 ABBVIE INC. $2,800.00 05/07/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202483551
Principal investigator 1 ABBVIE INC. $2,216.70 05/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481935
Principal investigator 1 ABBVIE INC. $2,308.50 05/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481977
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,104.26 04/28/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244048541
Principal investigator 1 PFIZER INC. $6,567.89 04/24/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228853471
Principal investigator 1 ABBVIE INC. $2,540.00 04/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202473421
Principal investigator 1 ABBVIE INC. $22,960.00 04/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202473425
Principal investigator 1 ABBVIE INC. $2,039.00 04/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202473429
Principal investigator 1 ABBVIE INC. $4,700.70 04/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202473433
Principal investigator 1 ABBVIE INC. $1,400.00 03/07/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
P24-880 - Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202460268
Principal investigator 1 ABBVIE INC. $11,346.75 03/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202457197
Principal investigator 1 ABBVIE INC. $2,096.55 03/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202457201
Principal investigator 1 ABBVIE INC. $1,959.00 03/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202457205
Principal investigator 1 ABBVIE INC. $6,978.15 02/05/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202444167
Principal investigator 1 ABBVIE INC. $8,275.50 02/05/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202444171
Principal investigator 1 ABBVIE INC. $1,858.00 02/05/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202444497
Principal investigator 1 Eli Lilly and Company $600.00 01/31/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES OF TUCSON
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1187886208
Principal investigator 1 PFIZER INC. $832.50 01/23/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228859099
Principal investigator 1 PFIZER INC. $764.46 01/16/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center INC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228859056
Principal investigator 1 Eli Lilly and Company $9,966.00 01/07/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187878723
Principal investigator 1 ABBVIE INC. $1,205.00 01/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202433742
Principal investigator 1 ABBVIE INC. $3,870.45 01/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202433809

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $68,970.59 1
PY2025 Value of interest $168,601.86 1
PY2024 Amount invested $40,296.41 1
PY2024 Value of interest $99,631.27 1
PY2023 Amount invested $17,103.46 1
PY2023 Value of interest $59,334.86 1
PY2022 Amount invested $17,804.01 1
PY2022 Value of interest $42,231.41 1
PY2021 Amount invested $7,696.81 1
PY2021 Value of interest $24,427.40 1
PY2020 Amount invested $8,096.07 1
PY2020 Value of interest $16,730.59 1
PY2019 Amount invested $8,290.25 1
PY2019 Value of interest $8,634.52 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $68,970.59 $168,601.86 Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. Payments are made to a group practice, not directly to the physician. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buy down per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1246692284
PY2024 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $40,296.41 $99,631.27 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice rather than to a specific physician. The group practice owns 50% of the GPO. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buydown per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1146408855
PY2023 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $17,103.46 $59,334.86 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice rather than to a specific physician. The group practice owns 50% of the GPO. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buydown per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1056981129
PY2022 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $17,804.01 $42,231.41 The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. Physician Covered Recipient No dispute reported 06/30/2026 962020747
PY2021 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $7,696.81 $24,427.40 The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. Physician Covered Recipient No dispute reported 06/30/2026 851041375
PY2020 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $8,096.07 $16,730.59 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 753247345
PY2019 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $8,290.25 $8,634.52 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 708351947